Many biopharmaceutical companies are facing challenges raising cash through traditional equity markets. While venture investment activity saw a slight increase in the first half of 2024 as compared to the equivalent period in...more
9/5/2024
/ Biotechnology ,
Capital Formation ,
Capital Markets ,
Debt Financing ,
Equity Financing ,
Equity Markets ,
Initial Public Offering (IPO) ,
Intellectual Property Agreements ,
IP License ,
Life Sciences ,
Revenue Growth ,
Royalties ,
Sale of Assets ,
Venture Capital
The London Interbank Offered Rate (LIBOR) officially ceased to be published on June 30, 2023. The change comes after almost 40 years of LIBOR serving as the principal benchmark rate for trillions of dollars of various...more
Uncertainty over the scope and spread of the COVID-19 outbreak continues to negatively impact the domestic and worldwide economy. Disruptions to business as a result of stay-at-home or shelter-in-place orders, restrictions on...more
If your business carries debt, the interest rate on that debt is likely to be linked to the London Interbank Offered Rate (LIBOR). LIBOR has been the standard benchmark rate for a variety of financial products since the early...more